Ana Calvo

Ana Calvo

Auto-generated profile, based on publicly available information

Ana Calvo

School of Psychology, Universidad Complutense de Madrid, Madrid, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Schizophrenia Research
Verified
Journal Article
Closed access
MRMarta Rapado-Castro
Marta Rapado-Castro
PMPatrick D. McGorry
Patrick D. McGorry
AYAlison Yung
Alison Yung
ACAna Calvo
Ana Calvo
BNBarnaby Nelson
Barnaby Nelson

1 September 2021 in Schizophrenia Research
Verified
Journal Article
Closed access
SBSara Barbeito
Sara Barbeito
PVPatricia Vega
Patricia Vega
TSTeresa Sanchez-Gutierrez
Teresa Sanchez-Gutierrez
JBJuan Antonio Becerra-García
Juan Antonio Becerra-García
AGAna González-Pinto
Ana González-Pinto
ACAna Calvo
Ana Calvo

1 June 2014 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
ACAna Calvo
Ana Calvo
MMMiguel Moreno
Miguel Moreno
ARAna Ruiz-Sancho
Ana Ruiz-Sancho
MRMarta Rapado-Castro
Marta Rapado-Castro
CMCarmen Moreno
Carmen Moreno
MMMaria Mayoral
Maria Mayoral

1 February 2020 in Journal of Affective Disorders
Verified
Journal Article
Closed access
SBSara Barbeito
Sara Barbeito
TSTeresa Sanchez-Gutierrez
Teresa Sanchez-Gutierrez
JBJuan Antonio Becerra-García
Juan Antonio Becerra-García
APAna González Pinto
Ana González Pinto
ECElisabetta Caletti
Elisabetta Caletti
ACAna Calvo
Ana Calvo

6 December 2022 in Psychological Medicine
Verified
Journal Article
Open access
PDF file
CMCarla Morales-Pillado
Carla Morales-Pillado
BFBelén Fernández-Castilla
Belén Fernández-Castilla
TSTeresa Sánchez-Gutiérrez
Teresa Sánchez-Gutiérrez
EGEduardo González-Fraile
Eduardo González-Fraile
SBSara Barbeito
Sara Barbeito
ACAna Calvo
Ana Calvo
Background: Technology-based interventions (TBIs) are a useful approach when attempting to provide therapy to more patients with psychosis.Methods: Randomized controlled trials of outcomes of TBIs v. face-to-face interventions in psychosis were identified in a systematic search conducted in PubMed/Ovid MEDLINE. Data were extracted independently by two researchers, and standardized mean changes were pooled using a three-level model and network meta-analysis.Results: Fifty-eight studies were included. TBIs complementing treatment as usual (TAU) were generally superior to face-to-face interventions (g = 0.16, p ≤ 0.0001) and to specific outcomes, namely, neurocognition (g = 0.13, p ≤ 0.0001), functioning (g = 0.25, p = 0.006), and social cognition (g = 0.32, p ≤ 0.05). Based on the network meta-analysis, the effect of two TBIs differed significantly from zero; these were the TBIs cognitive training for the neurocognitive outcome [g = 0.16; 95% confidence interval (CI) 0.09–0.23] and cognitive behavioral therapy for quality of life (g = 1.27; 95% CI 0.46–2.08). The variables educational level, type of medication, frequency of the intervention, and contact during the intervention moderated the effectiveness of TBIs over face-to-face interventions in neurocognition and symptomatology.Conclusions: TBIs are effective for the management of neurocognition, symptomatology, functioning, social cognition, and quality of life outcomes in patients with psychosis. The results of the network meta-analysis showed the efficacy of some TBIs for neurocognition, symptomatology, and quality of life. Therefore, TBIs should be considered a complement to TAU in patients with psychosis.

31 January 2020 in European Psychiatry
Verified
Journal Article
Open access
PDF file
TSTeresa Sanchez-Gutierrez
Teresa Sanchez-Gutierrez
BFBelén Fernandez-Castilla
Belén Fernandez-Castilla
SBSara Barbeito
Sara Barbeito
AGAna González-Pinto
Ana González-Pinto
JBJuan Antonio Becerra-García
Juan Antonio Becerra-García
ACAna Calvo
Ana Calvo
Background.: The implications of cannabis use in the onset of early psychosis and the severity of psychotic symptoms have resulted in a proliferation of studies on this issue. However, few have examined the effects of cannabis use on the cognitive symptoms of psychosis (i.e., neurocognitive functioning) in patients with first-episode psychosis (FEP). This systematic review and meta-analysis aim to assess the neurocognitive functioning of cannabis users (CU) and nonusers (NU) with FEP.Methods.: Of the 110 studies identified through the systematic review of 6 databases, 7 met the inclusion criteria, resulting in 14 independent samples and 78 effect sizes. The total sample included 304 CU with FEP and 369 NU with FEP. The moderator variables were age at first use, duration of use, percentage of males, and age.Results.: Effect sizes were not significantly different from zero in any neurocognitive domain when users and NU were compared. Part of the variability in effect sizes was explained by the inclusion of the following moderator variables: (1) frequency of cannabis use (β= 0.013,F= 7.56,p= 0.017); (2) first-generation antipsychotics (β= 0.019,F= 34.46,p≤ 0.001); and (3) country where the study was carried out (β= 0.266,t= 2.06,p= 0.043).Conclusions.: This meta-analysis indicates that cannabis use is not generally associated with neurocognitive functioning in patients with FEP. However, it highlights the deleterious effect of low doses of cannabis in some patients. It also stresses the importance of the type of antipsychotic prescription and cannabis dose as moderator variables in the neurocognitive functioning of CU with FEP.